A carregar...
Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs
The recently conducted ADAURA trial concludes daily dosing of adjuvant osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), improves disease-free survival with stage IB/II/IIIA EGFR -mutated non-small cell lung cancer patients in comparison to placebo. We have developed a preclinica...
Na minha lista:
| Publicado no: | Transl Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Neoplasia Press
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8236545/ https://ncbi.nlm.nih.gov/pubmed/33993094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2021.101111 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|